Dougados M, Wei JCC, Landewe R, et al. - Researchers sought to evaluate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of individuals with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive (COAST-V) or tumour necrosis factor inhibitor (TNFi)-experienced (COAST-W). In this study, adults with active r-axSpA were assigned randomly 1:1:1:1 (n = 341) to 80 mg ixekizumab every 2 (IXE Q2W) or 4 weeks (IXE Q4W), placebo (PBO) or 40 mg adalimumab Q2W (ADA) in COAST-V and 1:1:1 (n=316) to IXE Q2W, IXE Q4W or PBO in COAST-W. In bDMARD-naive and TNFi-experienced individuals, the significant efficacy illustrated with ixekizumab at week 16 was sustained for up to 52 weeks. The results revealed that bDMARD-naive individuals initially treated with ADA showed further numerical improvements after switching to ixekizumab. They demonstrated that safety findings were consistent with the known safety profile of ixekizumab.